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Abstract
Background: Acute myeloid leukemia (AML) accounts for more than two thirds of leukemia during pregnancy and
has an incidence of 1 in 75,000 to 100,000. Its clinical management remains a challenging therapeutic task both for
patient and medical team, given to the therapy-attributable risks for mother and fetus and the connected
counseling regarding pregnancy continuation.
Methods: We provided a review of updated literature and a comprehensive description of five maternal/fetal
outcomes of AML cases diagnosed concomitantly to pregnancy and treated at our Institution from 2006 to 2012.
Results: Median age at AML diagnosis was 32 years (31–39). One diagnosis was performed in first trimester and the
patient asked for therapeutic abortion before starting chemotherapy. Three cases were diagnosed in second/third
trimester; in one case leukemia was diagnosed concomitantly with intrauterine fetal death, while the remaining two
patients continued pregnancy and delivered a healthy baby by cesarean section. In only one of these two cases
chemotherapy was performed during pregnancy (at 24 + 5 weeks) and consisted of a combination of
daunorubicine and cytarabine. Therapy was well tolerated and daily fetus monitoring was performed. After
completion of 30 weeks of gestation a cesarean section was carried out; the newborn had an Apgar score of 5/1'-
7/5'-9/10', oxygen therapy was temporarily given and peripheral counts displayed transient mild leukopenia. One
patient had diagnosis of myelodysplastic syndrome rapidly progressed to AML after delivery. Four out of the 5
described women are currently alive and disease-free. Three children were born and long-term follow-up has
shown normal growth and development.
Conclusions: The treatment of AML occurring during pregnancy is challenging and therapeutic decisions should
be taken individually for each patient. Consideration must be given both to the immediate health of mother and
fetus and to long-term infant health. Our series confirmed the literature data: fetal toxicity of cytostatic therapy
clusters during the first trimester; while chemotherapy can be administered safely during second/third trimester and
combination of daunorubicin and cytarabine is recommended for induction.
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Background
Cancer is diagnosed in about 0.07% to 0.1% of pregnancies
and represents the second most common cause of maternal
death after gestation-related vascular complications [1–7].
Pregnant women showed the same cancer frequency and
localization when compared to nonpregnant ones of the
same age [2]. The majority of described cases are solid
tumors; oncohematologic diseases represent 25% of all
cancers diagnosed during pregnancy [1–7]. The incidence
of leukemia during gestation is estimated to range from 1
in 75,000 to 100,000 pregnancies, although its real epidemi-
ology remains poorly defined [1–7]. Acute myeloid
leukemia (AML) accounts for two-thirds of all cases, while
acute lymphoid leukemia, chronic leukemia or myelodys-
plastic syndrome are rarely described [2–6]. Acute leukemia
is usually reported during the second and third trimesters
of pregnancy, accounting for 37% and 40% of the cases
respectively [3–8]. In the first trimester the incidence is
generally estimated around 23%, even if an underreporting
bias caused by spontaneous pregnancy termination could
not be excluded [3–8].
The rarity of hematologic neoplasia during pregnancy
has precluded prospective controlled trials; hence, data
are restricted to retrospective series and case reports,
with the related difficulties in establishing management
guidelines. Evidence obtained so far are insufficient for
determining a causative association between pregnancy
and hematological cancers [4].
Appropriate leukemia treatment has significantly
improved survival and the central role of specific therapy
during gestation has been emphasized while clinical experi-
ence accumulates [1, 7–16].
The therapeutic approaches to leukemia during preg-
nancy may be conditioned by several variables, including
the gestational age at diagnosis, the clinical and biological
disease characteristics, and the potential drug toxicity on
mother and child [16–24].
Herein, we describe fetal and maternal outcomes of five
cases of acute myeloid leukemia occurring during
pregnancy consecutively diagnosed and treated at our Insti-
tution in order to make useful suggestions in the manage-
ment of acute myeloid leukemia during pregnancy.
Methods
Five patients with AML, diagnosed during or immedi-
ately after pregnancy, were identified in the institutional
database between 2006 and 2012.
AML diagnosis was performed according to World
Health Organization (WHO) 2008 diagnostic criteria for
the cases diagnosed from 2008 to 2012 [25], and accord-
ing to WHO 2001 for those diagnosed before 2008 [26].
Baseline clinical data, pregnancy characteristics, treat-
ment modalities, efficacy, safety and disease courses were
extracted by carefully reviewing all clinical data-sources
represented by original paper-based patient and electronic
records (medical and nursing paper-notes, blood
chemistry, blood counts and coagulation tests, histological
reports, echocardiography, radiological examinations and
other diagnostic procedures).
Histological analysis of placenta was performed by
local pathologists for each patient.
All procedures followed were in accordance with the
ethical standards of the Helsinki Declaration of 1975, as
revised in 2008.
Results
A summary of the therapeutic regimen, gestational age,
delivery method, mothers’ and infants’ outcomes is
presented in Table 1.
Clinical case 1
A 31 years old woman from Sri Lanka at 14 weeks gesta-
tional age, during a routine control, showed a decrease of
body weight and leucopenia [white blood cell (WBC)
3.65 × 109/L]. The mother was pregnant for the second
time, with a caesarian section performed 3 years before
for a cervical dystocia. The bone marrow aspirate demon-
strated a diagnosis of AML without maturation (WHO
2008). Cytogenetic analysis showed a normal karyotype.
Fluorescence in situ hybridization (FISH) karyotyping was
negative for inv.(16) and t(8;21). The patient displayed
D835 FLT3 mutation in the tyrosin-kinase domain.
Five days after multidisciplinary consulting the patient
asked for surgical abortion. The procedure was
performed without complications and after one week the
patient started chemotherapy.
Induction chemotherapy with daunorubicin and cytosine
arabinoside was performed, and a partial remission was
obtained (Table 1). A second induction with FLAG-IDA
regimen was administered, obtaining complete remission
(CR). Consolidation therapy was completed with allogeneic
myeloablative hematopoietic stem cell transplantation
(HSCT) from an HLA identical sister (Table 1). The patient
is alive and well with a follow up of 54 months.
Clinical case 2
A 36 years old Caucasian woman at 32 weeks gestational
age at her fourth pregnancy, was referred to our Center for
a suspected HELLP syndrome. On admission peripheral
blood counts and coagulation tests displayed WBC
3.4 × 109/L, hemoglobin (Hb) 8.2 g/dl, platelets 27 × 109/L,
fibrinogen 156 mg/dl, D-Dimer 13,675 μg/mL. Lactate
dehydrogenase was increased (689 U/L). An urgent
cesarean section was performed and a morphologic normal
male weighting 2290 g was born. The bone marrow aspir-
ate demonstrated a diagnosis of acute monoblastic
leukemia (WHO 2001). Cytogenetic analysis was unsuc-
cessful for absence of metaphases. FISH was negative for
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inv.(16) and t(8;21). Induction chemotherapy with dauno-
rubicin and cytosine arabinoside was performed and it was
complicated by disseminated intravascular coagulation
treated with fresh frozen plasma infusions. CR was
documented at bone marrow examination. Consolidation
treatment is reported in detail in Table 1. The patient is
alive and in good health after a follow up of 96 months.
Clinical case 3
A 32 years old Caucasian woman showed rapid decrease
of peripheral blood counts over a three months period.
The patient underwent a previous cesarean section for
breech presentation and a previous spontaneous abortion
at 9 gestational weeks. On admission she was at the 26th
gestational week and showed severe pancytopenia (Hb
8.6 g/dl, platelets 81 × 109/L, WBC 3.32 × 109/L). At
ultrasound examination fetus had regular morphology and
normal growth. We decided for a watch and wait strategy,
with close monitoring of fetal growth by ultrasound exam-
ination and cardiotocography, and performing filtered
Table 1 Characteristics of cases of AML treated during
pregnancy at our Istitution
Clinical case 1
Mother’s age,
years
31
Gestational
age, weeks
14
Induction
chemotherapy
-Induction: daunorubicin 50 mg/m2 (days 1, 3, 5)
and cytosine arabinoside 3 g/m2 (days 1–5)
-Reinduction: fludarabine 30 mg/m2 (days 1–4),
cytosine arabinoside 2 g/m2 (days 1–4)
and idarubicin 12 mg/m2 (days 1–4)
Consolidation
treatment
-Cytosine arabinoside 3 g/m2 twice a day
(days 1–3-5)
-Myeloablative sibling HSCT
(conditioning regimen: busulfan
0,8 mg/kg three times a day days
−9 -8 -7 -6 and cyclophosphamide
60 mg/kg days −3 -2)
Maternal outcome CR
Fetal outcome Surgical abortion at AML diagnosis
Delivery -
Clinical case 2
Mother’s
age (years)
36
Gestational
age (weeks)
32
Induction
chemotherapy
Daunorubicin 50 mg/m2 (days 1, 3, 5)
and cytosine arabinoside 3 g/m2 (days 1–5)
Consolidation
treatment
-Cytosine arabinoside 3 g/m2 twice a day
(days 1–4), daunorubicin 50 mg/m2 (days 5–6)
-Cytosine arabinoside 300 mg/m2 (days 1–5),
daunorubicin 50 mg/m2 (days 1–2)
-Cytosine arabinoside 300 mg/m2 (days 1–5),
etoposide 150 mg/m2 (days 1–3)
-Cytosine arabinoside 1 g/m2 twice a
day (days 1, 3, 5)
-Autologous HSCT (conditioning regimen:
cytosine arabinoside 3 g/m2 twice a day,
cyclophosphamide 60 mg/kg twice a day
for two days, 1000 cGy of total body irradiation)
Maternal outcome
Fetal outcome
Delivery
CR
Live birth, normal child
Cesarean at AML diagnosis
Clinical case 3
Mother’s age (years) 32
Gestational age
(weeks)
26
Induction
chemotherapy
Cytosine arabinoside 2 g/m2 twice a day
(days 1, 2, 8, 9) and idarubicin 18 mg/m2
(days 2, 3, 10) 6 weeks after delivery when
MDS progressed to AML
Consolidation
treatment
-Cytosine arabinoside 100 mg/m2 (days 1–7),
idarubicin 10 mg/m2 (days 1–3)
-Myeloablative sibling HSCT
(conditioning regimen: busulfan 0.8 mg/kg
three times a day, days −9 -8 -7 -6,
cyclophosphamide 60 mg/kg, days −3 -2)
Maternal outcome
Fetal outcome
CR
Live birth, normal child
Table 1 Characteristics of cases of AML treated during
pregnancy at our Istitution (Continued)
Delivery Cesarean at 32 + 2 weeks after
administration of betamethasone
Clinical case 4
Mother’s age
(years)
34
Gestational
age (weeks)
31
Induction
chemotherapy
Cytosine arabinoside 3 g/m2 (days 1–5)
and daunorubicin 50 mg/m2 (days 2, 4, 5)
Consolidation
treatment
-Cytosine arabinoside 3 g/m2 twice a
day (days 1–4), daunorubicin
50 mg/m2 (days 5–6)
−2 cycles of cytosine arabinoside 3 g/m2
twice a day (days 1–3-5)
Maternal outcome
Fetal outcome
Delivery
CR
Intrauterine fetal death
Cesarean at AML diagnosis
Clinical case 5
Mother’s
age (years)
39
Gestational
age (weeks)
24 + 5
Induction
chemotherapy
Cytosine arabinoside 100 mg/m2 (days 1–7)
and daunorubicin 40 mg/m2 (days 1–3)
Consolidation
treatment
4 cycles of cytosine arabinoside 3 g/m2
twice a day (days 1–3-5)
Maternal
outcome
CR; death for septic shock during the fourth
and last consolidation cycle with high
dose cytosine arabinoside
Fetal outcome
Delivery
Live birth, normal child
Cesarean at 30 weeks after
administration of betamethasone
CR complete remission, HSCT hematopoietic stem cell transplantation
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hemocomponents transfusions to maintain Hb >8 g/dl and
platelets >20 × 109/L. At the same time, betamethasone
12 mg i.m. was administered for fetal lungs maturation.
The bone marrow aspirate demonstrated a diagnosis of
refractory anemia with excess of blasts-1 (WHO 2008),
with a intermediate-1 IPSS risk class (score 1) [27].
The pregnancy was terminated by elective cesarean
section at 32 + 2 weeks of gestation without complications.
Placenta histological examination displayed normal find-
ings. The first evaluation of bone marrow and flow-
cytometry analysis 6 weeks after delivery showed disease
progression to AML with myelodysplasia-related changes
(WHO 2008). Cytogenetic analysis showed a normal
karyotype. Induction chemotherapy with daunorubicin and
cytosine arabinoside was performed obtaining a CR at bone
marrow examination. Consolidation treatment is reported
in detail in Table 1. Allogeneic myeloablative HSCT was
performed from an HLA identical brother. The patient is
alive and in good health after a follow up of 36 months after
transplantation without major complications.
Clinical case 4
A 34 years old Caucasian woman at 31 weeks gestational
age, developed important abdominal pain, asthenia and
fever. The patient had in her obstetric history a previous
abortion, an unsuccessful medically assisted fertilization
procedure, and a spontaneous pregnancy with elective
cesarean delivery. On admission, ultrasonography showed
an in utero still birth. An urgent cesarean section was per-
formed and a death fetus weighing 1865 g was extracted.
No surgical adverse event was reported.
Peripheral blood counts and coagulation tests displayed
WBC 5.32 × 109/L, platelets 49 × 109/L, D-Dimer 4689 μg/
ml, fibrinogen 167 mg/dl. Lactate dehydrogenase was
increased (1008 U/L).
Histological analysis of placenta revealed multiple recent
infarcts, intraplacentar ematomas with infarctions of sur-
rounding parenchima and not recent subchorial throm-
boses, with regular villous maturation and branching of
the cotyledons appropriate for 31 gestational weeks. Acute
myeloid leukemia cells (MPO + CD34-CD7-) were limited
to intervillous maternal space (Figs. 1, 2). Bone marrow
aspirate revealed a diagnosis of AML without maturation
(WHO 2001). Cytogenetic was normal and FISH karyo-
typing was negative for t(15;17), inv.(16) and t(8;21).
FLT3-ITD and NPM1 mutation were both present. Induc-
tion chemotherapy with daunorubicin and cytosine arabi-
noside was performed. The clinical course was
complicated by fungal liver infection. After hepatitis reso-
lution, CR was documented at bone marrow examination.
Consolidation treatment is reported in detail in Table 1.
The patient is alive and in good health after a follow up of
53 months.
Clinical case 5
A 39 years old Caucasian woman was referred to our Insti-
tution for severe pancytopenia at routine peripheral blood
examination. Blood counts showed WBC 16 × 109/L, Hb
5.1 g/dl, platelets 47 × 109/L. Myeloid blasts in peripheral
blood were 74%. Coagulation parameters were normal. She
was at her second pregnancy with a previous low transverse
caesarian section for macrosomia after intracytoplasmatic
sperm injection. At the moment of the referral, she was at
24 + 5 weeks of spontaneous conception pregnancy by
menstrual age. Ultrasound examination described a single
fetus at 22 + 4 weeks gestation with normal anatomy, amni-
otic fluid and umbilical artery doppler systolic–diastolic
Fig. 1 a Clinical case 4, acute myeloid leukemia cells limited to
intervillous maternal space, which is indicated by the asterisk.
Hematoxylin-eosin staining. The area pointed out by the arrow is
magnified in Fig. 1(B). b Myeloblasts show mild size variation, have
pale to slightly basophilic agranular cytoplasm and uniform large nu-
clei with condensed chromatin. Blast cells are pointed out by
the arrow
Fig. 2 Clinical case 4, immunohistochemical staining for
myeloperoxidase highlights myeloblasts in the intervillous maternal
space, which is pointed out by the asterisk
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ratio. Intramuscular betamethasone was administered for
fetal lung maturation. Bone marrow aspirate revealed a
diagnosis of acute monoblastic leukemia (WHO 2008).
FISH analysis was positive for inv.(16). The patient was
transferred to the intensive care unit for strict monitoring.
Induction chemotherapy with daunorubicin and cyto-
sine arabinoside was performed. Daily ultrasound and
tocographic monitoring of fetal status was performed.
CR was documented at bone marrow examination. After
the completion of 30 weeks of gestation, a cesarean
section under general anesthesia was performed.
A morphologic normal male weighting 1495 g was born.
Apgar score at birth was 5/1′- 7/5′ - 9/10′. Oxygen ther-
apy was given to the newborn and he was transferred to
the neonatal intensive care unit.
Four days after cesarean section the patient was trans-
ferred to the oncohematology ward to continue leukemia
treatment. During the last consolidation cycle, the woman
died for a septic shock causing multiorgan failure.
Children outcomes
In the described population, one case of AML was diag-
nosed concomitantly with intrauterine fetal death; only
one patient asked for a therapeutic abortion before start-
ing chemotherapy. The three remaining patients contin-
ued a regular pregnancy and delivered a healthy baby.
Only one child was exposed to chemotherapy during the
gestational period (clinical case 5). The newborn needed
oxygen therapy immediately after birth and suffered of a
mild leukopenia, which resolved spontaneously after a few
days. He is 5 years old and currently followed at our Institu-
tion according to the local clinical guidelines. All tests
performed testified a normal neurodevelopment and no
impairments to general health and growth, including a nor-
mal cardiac outcome by echocardiography. The other two
children were born by a cesarean delivery at AML diagnosis
and before the start of a chemotherapy program; physical
evaluations and standard blood examinations were normal
at birth and at the time of last available follow-up when
they were 1 and 5 years old, respectively.
Discussion
We report here the diagnosis, treatment and outcome of
five consecutive cases of acute myeloid leukemia during
pregnancy, occurred from 2006 to 2012 in a single
Hematologic Unit.
The clinical picture of AML presenting during pregnancy
is similar to that of non-pregnant women, and the diagnos-
tic criteria are those defined in the WHO classification of
myeloid neoplasms [25, 26]. The overlap of some common
symptoms reported during pregnancy, such as fatigue and
shortness of breath, or physiologic alteration of peripheral
blood counts, as anemia and thrombocytopenia, might
delay the diagnostic suspicion and appropriate therapy. In
this respect, the main differential diagnoses to consider are
thrombotic microangiopathy, HELLP syndrome and cyto-
penias of deficiency or immune origin [7].
Acute leukemia may present with hyperleukocytosis,
thromboses or disseminated intravascular coagulation, in
the context of a gestational associated thrombogenic mi-
lieu [1–5]. Thrombosis could affect placental vessels,
impairing fetal growth and survival [28, 29]. Intrauterine
death may also be the result of hypoxia caused by placen-
tal ischaemic infarction and leukemic infiltration [1–5], as
occurred in one of the patients described in this series.
Essential investigations for a correct differential diagno-
sis should include full blood count and blood film examin-
ation, vitamin B12, folate and ferritin measurement,
coagulation and hemolysis screening, renal and liver func-
tion tests [7]. When a diagnosis of leukemia is suspected,
marrow samples should be obtained and morphological,
immunophenotypic, cytogenetic and molecular analyses
performed to allow accurate sub-typing and correct prog-
nostication, according to published guidelines [30].
AML associated to pregnancy is rare and only small
patients series have been reported [1–15]. The anti-
leukemic therapies during pregnancy may differ from
golden standards, being conditioned by several variables,
including the gestational age at diagnosis, the clinical
and biological characteristic of the disease, and the po-
tential drugs toxic effects on mother and child [6–15].
Fetal toxicity of cytostatic therapy clusters during the
first trimester, while it declined dramatically during the
second and third ones [1–7, 15–24]. During the first tri-
mester chemotherapy results in fetal death in about 40%
of cases, while the percentage is about 10% during the
second trimester and almost the totality of infants who
were exposed to chemotherapy in the third trimester
were born alive with no major malformations, despite
cases of growth retardation, intellectual impairment, re-
duced fertility and hematopoietic suppression have been
reported [1–7, 15–24]. In most of the described cases,
patients diagnosed during the first trimester underwent
abortion and subsequently were treated with induction
chemotherapy [6–15].
In the few cases treated with chemotherapy during the
first trimester, poor pregnancy outcomes were reported with
congenital anomalies and spontaneous abortions, while it
was suggested that a prolonged delay in therapy initiation
may be associated with a worse maternal outcome [6–15].
When a diagnosis of AML associated to pregnancy is
made, a multidisciplinary team must be created to coordin-
ate all the diagnostic and therapeutic steps, including the
planning of a cesarean delivery before or between courses
of chemotherapy and after maternal bone-marrow reconsti-
tution, to avoid maternal and neonatal pancytopenia.
To minimize risks for mother and fetus, a near term
cesarean delivery (>35–37 weeks) remains the main goal.
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Survival following delivery at or beyond 28 weeks gestation
are >90% in most large centers, but even higher (>95%) if
the delivery was at or beyond 32 weeks gestation [7].
If it is possible to postpone the initiation of the therapeutic
program, a cesarean section should be planned before
chemotherapy, or at peripheral blood counts recovery after
the treatment cycle. Chemotherapy should not be adminis-
tered after the 35th gestational week [1–7]. Intensive ultra-
sound monitoring is essential to document fetal growth,
development, cardiac function and placental status, as well as
tocographic daily assessment. When delivery is necessary at
an earlier gestational age (before 34 weeks), a pharmacologic
enhancement of fetal lung maturation by corticosteroids
should be considered [7]. Breast feeding is contraindicated
during the maternal anti-leukemic program [7].
The use of hydroxycarbamide before starting induction
chemotherapy should be avoided except in cases of hyper-
leukocytosis (WBC greater then 100 × 109/L) [7]. An alter-
native is leukapheresis, that allows rapid reduction of WBC
counts in symptomatic patients. Large experiences with this
procedure during AML in pregnancy are not available, but
the few described cases demonstrated that it is a feasible
emergency measure bridging to cytotoxic therapy [29]. The
leukapheresis must be performed by expert personnel, and a
careful monitoring of patient’s cardiocirculatory parameters,
blood counts, coagulation status and electrolyte balance, to-
gether with fetus’ cardiac function (cardiotocography) must
be guaranteed throughout the procedure. Continuous-flow
cell separators should be preferably used to ensure the low-
est extracorporeal volume, and saline or 5% human albumin
is commonly used as replacement fluid, while fresh frozen
plasma should be preferentially used in case of hemorrhagic
features for coagulation factors deficiencies or intravascular
coagulation [31].
A single chemotherapy cycle with daunorubicin and
cytarabine is recommended for induction (daunorubicin
60 mg/m2 on days 1–3 and cytarabine 100 mg/m2 con-
tinuous infusion on days 1–7) [7]. The use of cytarabine
at the same dosage, but for 10 days of infusion could be
considered and it represents the standard regimen in the
UK. [7] There are also no data to support the use of
higher dose of daunorubicin and this approach is not
recommended for increased toxicity [7]. Idarubicin, for
its lipophilic characteristics, has an increased placental
transfer and higher potential foetal toxicity, and there-
fore daunorubicin remains the anthracycline of choice
[12, 16–20, 23]. It is highly advisable to monitor fetal
cardiac function for anthracycline rare cardiotoxicity
and limb morphogenesis for teratogenic potential of
cytarabine (10%) [7, 16–24].
Standard consolidation therapy with the use of inter-
mediate or high dose cytarabine is preferred [7, 30].
Acute promyelocytic leukemia (APL) represents a
special situation. The information available on maternal
and fetal outcomes in pregnant women with APL is lim-
ited. It could be a significant problem because it is usually
associated with coagulopathy; platelet transfusions should
be considered to maintain a platelet count of more than
30 × 109/L and fresh frozen plasma for a fibrinogen level
higher than 150 mg/dl. The management during the first
trimester of pregnancy should be separated from that
arising in the second/third semester. All-trans retinoic
acid (ATRA) is the cornerstone of APL treatment, but it
can be potential teratogenic and should be avoided during
the first trimester. Similarly, arsenic trioxide has a high
potential embryotoxicity and cannot be recommend at
any stage of pregnancy. If the patient wish to preserve
fetus, anthracycline alone is recommended during the first
trimester. Treatment by ATRA alone during the second
and the third trimester until complete remission achieve-
ment can be proposed, delaying the administration of
chemotherapy after birth [32, 33].
Regarding the allowed supportive therapies during preg-
nancy, the first line antiemetic agent are the antihistamines,
cyclizine and promethazine; metoclopromide may induce
maternal dystonic reactions, therefore it should be considered
as a second line drug. Ondasentron could be administered
safely during the first trimester, while tropisetron is not per-
mitted because malformations in animals were reported [7].
The use of granulocyte colony stimulating factor during
gestation was rarely reported, but the available data seem to
suggest its safe use in the second and third trimesters [34].
Penicillins were not associated to injurious fetal effects,
with the exception of the combination amoxicillin and
clavulonate. Aminoglycosides, quinolones, sulphonamides
and tetracyclines are not permitted; while the main
systemic antifungal drug safely used was amphotericin B or
lipid derivates. If a transfusion is required, cytomegalovirus-
negative blood products represent the first choice [7].
Based on the available data, pregnant women with
AML treated with appropriate regimens by expert and
multidisciplinary teams, might obtain outcomes similar
to those of non pregnant woman, and the prognosis is
worse only when appropriate treatment is significantly
delayed [1–15].
In our series, induction treatment consisted of a com-
bination of anthracyclines and cytarabine; in particular,
the only patient treated before delivery received standard
dosage of cytarabine and daunorubicin at a reduced dos-
age of 40 mg/m2 (days 1–3). With a median follow-up of
6 years from diagnosis, overall survival is of 80% and
leukemia free survival is of 100%.
These results reproduce those observed for adolescents
and young adults (AYA) AML. The reasons of the im-
proved outcomes among AYA-AML, to which AML during
pregnancy may be associated, in comparison to their older
counterparts, include a multifactorial explanation, encom-
passing both patient/host (better performance status, few
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comorbidities, optimal intensive chemotherapy tolerance)
and AML disease biology (reduced incidence of high-risk
chromosomal abnormalities or multi-drug resistance
expression) [35].
Conclusions
The cases described here have represented for our institution
a clinical challenge that forced us to build a multidisciplinary
team involving hematologists, obstetricians, anesthesiologist
and pediatricians/neonatologists, in order to properly manage
all the phases of leukemia diagnosis and treatment, as well as
those concerning pregnancy and newborn.
The available therapeutic options were proposed to,
and the connected risks and alternatives were presented
and discussed with, each patient, by the different special-
ists involved in the team, always collegially.
In those cases diagnosed in advanced gestational age, we
postponed the leukemia treatment after delivery, performed
in all cases by carefully programmed caesarean section.
In the only case occurring in the first trimester, the
patient asked for therapeutic abortion. If chemotherapy is
administered during pregnancy, extensive and continuous
monitoring of fetus vital signs, cardiac function and con-
genital malformation is mandatory in order to promptly
diagnose and treat emerging complications related to the
disease or therapy. Cord blood stem cells should be col-
lected and stored in the event that an irreversible bone
marrow failure syndrome should develop in the fetus.
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